NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
Key figures
- Market capClose on Nov 13, 2026
- $2.42B
- Insider buysLast 90 days, $226.5K in total
- 1
- Insider sellsLast 90 days, $4.66M in total
- 3
- 13F holdersQ2 2026, 0 vs. previous quarter
- 9
- 13F valueReported value at the end of Q2 2026
- $28.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $22.5M
- −50.6% year over year
- Net income, FY2025
- -$203.8M
- No comparable prior period
- Free cash flow, FY2025
- -$148.0M
- No comparable prior period
- Revenue, Q3 FY2026
- $19.2M
- +5,406.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $203.8M (905.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 61
- Shares sold short
- Change
- +19
- +45.2% vs. previous
- Days to cover
- 1.00
- At average daily volume
Superinvestors holding NAMSW, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NAMSW at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by NewAmsterdam Pharma Co N.V. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Oct 2, 2026 (view filing)4:30 PM ET | Sep 30 | 2 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −50.2K | $25.03 | −$1.26M | −42.0%69.3K after | 10b5-1 |
| Sep 15, 2026 (view filing)4:30 PM ET | Sep 14 | 1 day | Davidson Michael H.Chief Executive Officer | PPurchase | +10.0K | $22.65 | +$226.5K | +1.3%792.9K after | |
| Sep 9, 2026 (view filing)4:30 PM ET | Sep 4 | 5 days | Smither John WDirector | SSale | −1.60K | $25.32 | −$40.5K | −15.4%8.76K after | |
| Aug 25, 2026 (view filing)4:30 PM ET | Aug 24 | 1 day | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −125.0K | $26.91 | −$3.36M | −64.3%69.3K after | 10b5-1 |
| Jul 22, 2026 (view filing)4:05 PM ET | Jul 20 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −105.0K | $30.34 | −$3.19M | −81.2%24.4K after | 3 lots10b5-1 |
| Jun 24, 2026 (view filing) | Jun 22 | 2 days | Kooij Louise FrederikaChief Accounting Officer | SSale | −40.0K | $30.20 | −$1.21M | −62.2%24.4K after | 2 lots10b5-1 |
| May 27, 2026 (view filing) | May 26 | 1 day | Kooij Louise FrederikaChief Accounting Officer | SSale | −65.0K | $35.69 | −$2.32M | −72.7%24.4K after | 10b5-1 |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Lange Louis GDirector | SSale | −44.6K | $30.42 | −$1.36M | −81.2%10.4K after | 2 lots |
| Mar 10, 2026 (view filing) | Mar 6 | 4 days | Lange Louis GDirector | SSale | −28.2K | $29.41 | −$829.0K | −100.0%0 after | |
| Mar 9, 2026 (view filing) | Mar 5-9 | 4 days | Kastelein Johannes Jacob PieterChief Scientific Officer | SSale | −300.0K | $30.30 | −$9.09M | −81.2%69.3K after | 3 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 9 holdersThe largest institutional positions in NewAmsterdam Pharma Co N.V. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 500,333 | $10.7M | 0.23% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 333,333 | $7.12M | 0.06% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 245,000 | $5.34M | 0.26% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 99,999 | $2.14M | 0.13% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 92,787 | $1.98M | 0.02% | 00.0% | Unchanged |
| Aristeia Capital LLC | 15,708 | $343.4K | 0.01% | 00.0% | Unchanged |
| Wolverine Asset Management LLC | 14,925 | $318.9K | 0.00% | +12,798+601.7% | Added |
| Vestcor Inc | 6,666 | $143.0K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 443 | $8.52K | 0.00% | +47+11.9% | Added |